EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Tamoxifen Reduces Breast Cancer Recurrence in Women with DCIS Who Underwent Mastectomy

Netchanok Sae-Sim, Norasate Samarnthai, Warapan Numprasit iD

Current Oncology · 2026

DOI: 10.3390/curroncol33020089 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Oncology, 2026. Verfasst von Netchanok Sae-Sim und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Head Neck and Breast Surgery, Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand. Hauptthemen laut MEDLINE: Tamoxifen, Breast Neoplasms, Mastectomy, Neoplasm Recurrence, Local. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Siriraj Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Adjuvant tamoxifen reduces recurrence in patients with ER-positive DCIS treated with lumpectomy and radiation, but its benefit after mastectomy remains unclear.

Methods

We retrospectively analyzed 287 patients who underwent mastectomy for pure DCIS at Siriraj Hospital between 2008 and 2017. Recurrence risk factors were assessed using log-rank test, and survival probabilities were estimated with Kaplan–Meier analysis.

Results

Of 180 patients with hormone receptor (HR)-positive pure DCIS treated with mastectomy, 120 (66.7%) received tamoxifen, while the remaining 60 (33.3%) did not. The median follow-up was 8.07 years (0.05–13.8 years). Sixteen (8.9%) recurrences were identified, with 5 in the tamoxifen group and 11 in non-endocrine-therapy (ET) group. The 10-year recurrence-free survival (RFS) was 94.7% in the tamoxifen group compared with 77.9% in the non-ET group. Patients with HR-positive DCIS treated with tamoxifen following mastectomy had significantly less subsequent breast cancer (HR = 0.178; p = 0.001).

Conclusions

Recurrence of breast cancer after mastectomy for DCIS is rare; however, it carries a high mortality rate for those who relapse. Adjuvant tamoxifen after mastectomy demonstrated a significant reduction in the risk of recurrence in ER-positive DCIS. This study supports the decision to prescribe adjuvant ET in patients with DCIS who underwent mastectomy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TamoxifenBreast NeoplasmsMastectomyNeoplasm Recurrence, LocalAntineoplastic Agents, HormonalCarcinoma, Intraductal, NoninfiltratingHumansFemaleRetrospective StudiesMiddle AgedAgedAdult

Stichwörter der Autor:innen

DCIScontralateral breast recurrenceendocrine treatmentpostmastectomy recurrence

Substanzen

TamoxifenAntineoplastic Agents, Hormonal

Autor:innen und Institutionen

  • Division of Head Neck and Breast Surgery, Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand.
  • Department of Pathology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand.

ORCID-Profile: Warapan Numprasit

Förderung

  • Siriraj Foundation

Zitieren

APA

Sae-Sim, N., Samarnthai, N., & Numprasit, W. (2026). Tamoxifen Reduces Breast Cancer Recurrence in Women with DCIS Who Underwent Mastectomy. Current Oncology. https://doi.org/10.3390/curroncol33020089

Vancouver

Sae-Sim N, Samarnthai N, Numprasit W. Tamoxifen Reduces Breast Cancer Recurrence in Women with DCIS Who Underwent Mastectomy. Current Oncology. 2026. doi:10.3390/curroncol33020089

BibTeX
@article{SaeSim2026,
  author = {Sae-Sim, Netchanok and Samarnthai, Norasate and Numprasit, Warapan},
  title = {Tamoxifen Reduces Breast Cancer Recurrence in Women with DCIS Who Underwent Mastectomy},
  journal = {Current Oncology},
  year = {2026},
  doi = {10.3390/curroncol33020089}
}
Kostenlos starten →